for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Apellis Pharmaceuticals Inc

APLS.OQ

Latest Trade

27.81USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.45

 - 

33.18

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Apellis Pharmaceuticals Says Currently Enrolling Two Global Confirmatory Phase 3 Studies For Patients With GA

Sept 18 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::PHASE 2 STUDY PUBLISHED IN OPHTHALMOLOGY HIGHLIGHTS EFFICACY AND SAFETY DATA OF INTRAVITREAL APL-2 FOR GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.APELLIS PHARMACEUTICALS INC - CURRENTLY ENROLLING TWO GLOBAL CONFIRMATORY PHASE 3 STUDIES FOR PATIENTS WITH GA.APELLIS PHARMACEUTICALS INC - PUBLICATION OF FULL STUDY REPORT FOLLOWS RELEASE OF TOPLINE STUDY RESULTS EARLIER THIS YEAR.APELLIS PHARMA - PUBLICATION OF REPORT SHOWS THAT TREATMENT WITH APL-2 RESULTED IN STATISTICALLY SIGNIFICANT REDUCTIONS IN GROWTH OF GA LESION AREA.

Apellis Pharmaceuticals Announces Pricing Of Offering Of Convertible Senior Notes

Sept 12 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF CONVERTIBLE SENIOR NOTES.APELLIS PHARMACEUTICALS INC - PRICING OF ITS OFFERING OF $220.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 3.500% CONVERTIBLE SENIOR NOTES DUE 2026.APELLIS PHARMACEUTICALS INC - APELLIS ESTIMATES THAT NET PROCEEDS FROM SALE OF NOTES WILL BE APPROXIMATELY $212.9 MILLION.APELLIS PHARMACEUTICALS INC - OFFERING IS EXPECTED TO CLOSE ON SEPTEMBER 16.

Apellis Pharmaceuticals Announces Proposed Private Offering Of $200 Mln Of Convertible Senior Notes

Sept 11 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES.APELLIS PHARMACEUTICALS INC - INTENDS TO OFFER 200 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2026.

Apellis Pharmaceuticals Reports Qtrly Loss Per Share $1.12

July 31 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC - EXPECTS TO INITIATE PHASE 3 COLD AGGLUTININ DISEASE (CAD) TRIAL IN EARLY 2020.APELLIS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $1.12.

Apellis Pharmaceuticals Inc Quarterly Loss Per Share $1.12

July 31 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $1.12.

Apellis Completes Enrollment of Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab

June 27 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 3 APL-2 (PEGCETACOPLAN) HEAD-TO-HEAD STUDY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH ECULIZUMAB.APELLIS PHARMACEUTICALS INC - APELLIS EXPECTS TO RELEASE TOP-LINE DATA IN DECEMBER 2019..APELLIS PHARMACEUTICALS INC - APELLIS EXPECTS TO RELEASE TOP-LINE DATA IN DECEMBER 2019..

Apellis Pharmaceuticals Qtrly Loss Per Share $0.87

May 8 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS REPORTS FIRST QUARTER 2019 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC - CASH POSITION OF $288.2 MILLION AT QUARTER-END.APELLIS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.87.

Apellis Pharmaceuticals Says Public Offering Of 6.00 Mln Common Shares Priced At $17.00Per Share

March 7 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 6.00 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.

Apellis Pharmaceuticals Announces Proposed Public Offering Of Common Stock

March 6 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.APELLIS PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF SHARES OF ITS COMMON STOCK.

Apellis Pharmaceuticals Announces Collaboration With SFJ Pharmaceuticals For APL-2 In Hematologic Indications

Feb 28 (Reuters) - Apellis Pharmaceuticals Inc <APLS.O>::APELLIS PHARMACEUTICALS ANNOUNCES COLLABORATION WITH SFJ PHARMACEUTICALS FOR APL-2 IN HEMATOLOGIC INDICATIONS.APELLIS PHARMACEUTICALS INC - APELLIS TO RECEIVE UP TO $120 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS FROM DEAL.APELLIS PHARMACEUTICALS INC - APELLIS RETAINS EXCLUSIVE WORLDWIDE COMMERCIAL RIGHTS TO APL-2 IN ALL INDICATIONS.APELLIS PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL PAYMENTS SUBJECT TO MUTUAL AGREEMENT.APELLIS PHARMA - SFJ MAY ALSO PAY CO ADDITIONAL $50 MILLION IN FUNDING FOR PNH CLINICAL PROGRAM FOLLOWING A SPECIFIED, PRE-DEFINED CLINICAL MILESTONE..APELLIS PHARMACEUTICALS - HAS OPTION TO BUY-OUT OF ALL OR PART OF MILESTONE PAYMENTS AT ANY TIME FOLLOWING REGULATORY APPROVAL AT A DISCOUNTED RATE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up